Clinical Trials Browser

Leukemia × visilizumab × Clear all

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Phase 3 Unknown

30 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Terminated

8 enrolled 11 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis